EU

Showing 15 posts of 244 posts found.

abbvie_0

AbbVie granted EU marketing authorisation for new arthritis drug

December 19, 2019
Business Services AbbVie, EC, EU, arthritis, rheumatoid arthritis

AbbVie have announced that the European Commission (EC) have granted marketing authorisation for RINVOQ (upadacitnib). It’s a daily selective reversible …

shutterstock_138095450

Transactions in the pharma sector: Through the EU merger review looking-glass

December 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, feature, mergers & acquisitions, pharma

With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …

astrazeneca_sign_sky

AstraZeneca’s Qtrilment scores European authorisation in type 2 diabetes

November 15, 2019
Medical Communications, Sales and Marketing AstraZeneca, EU, Europe, Qtrilmet, diabetes, pharma, type 2 diabetes

Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to …

Promising Phase 3 data for Sanofi’s Toujeo secures CHMP recommendation of label expansion in type 1 diabetes

November 4, 2019
Research and Development, Sales and Marketing EU, Sanofi, Type 1 diabetes, diabetes, pharma, toujeo

Sanofi took the opportunity at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts to …

European Commission approves Sanofi’s Dupixent in chronic rhinosinusitis with nasal polyposis

October 30, 2019
Research and Development, Sales and Marketing Dupixent, EU, Sanofi, pharma

Sanofi’s Dupixent (dupilumab) has secured European approval for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), it has emerged. …

brexit-hintergrund_web

“No deal” Brexit and life sciences: What happens?

October 21, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Europe, UK, brexit, no deal, no-deal, pharma

Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …

celltrion1

Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation

September 24, 2019
Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …

merckwindow_web

Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma

September 4, 2019
Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma

The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …

brexit_predictions

British and American healthcare professionals predict further delays to Brexit as Europeans expect no-deal

August 19, 2019
Sales and Marketing EU, UK, US, brexit, brexit delay, healthcare, no-deal, pharma

The majority of healthcare professionals in Europe, Britain and America think Brexit will happen. However they do not believe that …

28246711066_52e38bc591_z

EU unprepared for no-deal Brexit, health experts warn

August 12, 2019
Sales and Marketing EU, Euroepan Union, UK, brexit, pharma

European health experts have warned that a no-deal Brexit could worsen medicines shortages in the European Union. Speaking to Reuters, …

Sanofi’s Dupixent extended in Europe to cover adolescents in atopic dermatitis

August 6, 2019
Manufacturing and Production, Sales and Marketing EU, Europe, Sanofi, atopic dermatits, pharma

Sanofi has announced that European Commission (EC) has chosen to extend the marketing approval of its interleukin-4 (IL-4) and interleukin-13 …

Bayer’s Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation

July 30, 2019
Manufacturing and Production, Sales and Marketing Bayer, CHMP, Cancer, EU, Vitrakvi, pharma

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic …

28246711066_52e38bc591_z

No-deal Brexit could cause shortages and higher prices, healthcare distributors warn

June 19, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, UK, brexit, distribution, pharma, supply chain

The Healthcare Distribution Association (HDA) has warned MPs that Britain could face shortages of medicines if it were to leave …

Contract manufacturing services industry set to grow at CAGR of 10.6% between 2017-2027

June 19, 2019
Research and Development EU, Europe, biopharma, contract manufacturing services, manufacturing, pharma

The biopharmaceutical contract manufacturing market is expected to grow at a compound annual growth rate (CAGR) of 10.6% between 2017 …

european_commission_web_5

EU pharmaceutical industry lost €16.5 billion in sales as staff shift to patent infringing firms

June 19, 2019
Research and Development EU, counterfeit, generics, pharma, sales

A report from the European Union Intellectual Property Office (EUIPO) has said ‘counterfeit’ drugs cost the EU pharmaceutical industry €16.5 …

Latest content